¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Vascular Endothelial Growth Factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • growth acceleration
    ¼ºÀå°¡¼Ó
  • growth arrest line
    ¼ºÀåÁ¤Áö¼±
  • growth chart
    ¼ºÀå±â·ÏÁö
  • growth cone
    ¼ºÀå¿ø»Ô
  • growth curve
    ¼ºÀå°î¼±
  • growth cycle
    Áõ½ÄÁÖ±â
  • growth defect
    ¼ºÀå°áÇÔ
  • growth delay
    ¼ºÀåÁö¿¬
  • growth factor
    ¼ºÀåÀÎÀÚ
  • growth failure
    ¹ßÀ°ºÎÀü, ¼ºÀåºÎÀü
  • growth fraction
    ¼ºÀåºÐÀ²
  • growth hormone
    ¼ºÀåÈ£¸£¸ó
  • growth hormone-inhibiting hormone
    ¼ºÀåÈ£¸£¸ó¾ïÁ¦È£¸£¸ó
  • growth hormone-releasing hormone
    ¼ºÀåÈ£¸£¸ó¹æÃâÈ£¸£¸ó
  • growth inducer
    ¼ºÀåÀ¯¹ßÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • growth defect
    ¼ºÀå°áÇÔ
  • growth delay
    ¼ºÀåÁö¿¬
  • growth-onset diabetes
    Ãʱâ´ç´¢º´
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • excessive growth
    °úµµ¼ºÀå
  • exponential growth
    Áö¼öÁõ½Ä
  • exponential growth rate
    ´ë¼öÁõ½Ä·ü, Áö¼öÁõ½Ä·ü
  • fetal growth retardation
    žƼºÀåÁö¿¬
  • fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷¼ºÀåÀÎÀÚ
  • growth factor
    ¼ºÀåÀÎÀÚ
  • growth fraction
    ¼ºÀåºÐÀ²
  • hematopoietic growth factor
    Ç÷¾×Çü¼º¼ºÀåÀÎÀÚ, Á¶Ç÷¼ºÀåÀÎÀÚ
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • macrophage-derived growth factor
    Å«Æ÷½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • growth curvature
    ¼ºÀå°î¼±(¡­ÍØàÊ).
  • growth curve
    Áõ½Ä°î¼±, ¼ºÀå°î¼±.
  • growth curve
    Áõ½Ä°î¼±
  • growth curve, one-step
    ÀÏȸÁõ½Ä°î¼±
  • growth curve, single-step
    ÀÏȸÁõ½Ä°î¼±
  • growth cycle
    Áõ½ÄÁÖ±â
  • growth defect
    ¼ºÀå°áÇÔ
  • growth delay
    ¼ºÀåÁö¿¬
  • growth factor
    ¼ºÀå ÀÎÀÚ
  • growth factor
    ¼ºÀåÀÎÀÚ(à÷íþì×í­).
  • growth factor
    Áõ½ÄÀÎÀÚ
  • growth factor
    ¼ºÀå ÀÎÀÚ(à÷íþ ì×í­)
  • growth factor, B cell (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • growth failure
    ¼ºÀåºÎÀü(à÷íþÝÕîï).
  • growth form
    ¼ºÀåÇü(¡­úþ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • primary vascular lesions
    ¿ø¹ß(¼º) Ç÷°ü°è º´º¯
  • pulmonary vascular resistance
    ÆóÇ÷°üÀúÇ×(øËúìηî½ù÷), Æó¼øÈ¯ÀúÇ×.
  • renal vascular disorder
    ½ÅÇ÷°üÁúȯ
  • renal vascular injury
    ½Å Ç÷°ü¼Õ»ó
  • reticulate vascular nevus
    ¸Á»ó Ç÷°ü ¸ð¹Ý
  • reticulated vascular nevus
    ¸Á»ó Ç÷°ü ¸ð¹Ý
  • skin vascular permeability factor
    ÇǺÎÇ÷°ü Åõ°úÀÎÀÚ
  • splanchnic vascular bed
    ³»ÀåÇ÷°ü¿µ¿ª(¡­úìηçÐæ´).
  • submucous vascular plexus
    Á¡¸·¹Ø¸Æ°ü¾ó±â
  • synthetic vascular graft
    ÇÕ¼ºÇ÷°ü(¡­úìη), ´ë¿ëÇ÷°ü(ÓÛéÄúìη).
  • total vascular resistance
    ÃÑÇ÷°üÀúÇ×(õÅúìη î½ù÷).
  • vascular
    ¸Æ°üÀÇ, Ç÷°üÀÇ.
  • vascular
    ¸Æ°ü(ØæÎ·)ÀÇ, Ç÷°üÀÇ
  • vascular anomaly
    Ç÷°ü ±âÇü
  • vascular bed
    Ç÷°ü»ó(úìηßÉ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
HFD hemorrhagic fever of deer; high-fiber diet; high forceps delivery; hospital field director; human fa...
PF1-4 platelet factors 1 to 4
PQRST provocative and palliative factors, quality of pain, radiation of pain, severity of pain, timing of ...
PULSES physical condition, upper limb function, lower limb function, sensory component, excretory function,...
IDA   1) Imino-Diacetic Acid
  2) Iron Deficiency Anemia
   &nb...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
VEC Vascular Endothelial Cells
VE Vascular endothelial
VE cadherin Vascular endothelial cadherin
ECGF Endothelial Cell Growth Factor
ECGS Endothelial Cell Growth Supplement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • vascular layer
    ¸Æ°üÃþ, Ç÷°üÃþ
  • vascular layer of lens
    ¼öÁ¤Ã¼ ¸Æ°üÃþ
  • vascular malformation
    Ç÷°ü ±âÇü
  • vascular murmur
    Ç÷°ü ÀâÀ½
  • vascular network
    ¸Æ°ü ±×¹°
  • vascular nevus
    ¸Æ°ü ¸ð¹Ý
  • vascular pain
    Ç÷°ü¼º ÅëÁõ
    Ç÷°ü¿¡ ºÐÆ÷ÇÏ´Â ±¸½É ½Å°æÀ¸·ÎºÎÅÍ À¯·¡ÇÏ´Â ³»Àå ±Ù¿ø¼º ½ÉºÎ ü¼º ÅëÁõ.
  • vascular permeability
    Ç÷°ü Åõ°ú¼º
    ³»ÇÇ ¼¼Æ÷¶ó´Â À庮À» »çÀÌ¿¡ µÎ°í ü¾×ÀÇ ÆòÇüÀº ¸ð¼¼Ç÷°ü ³» Ç÷¾×ÀÇ ¼ö·ÂÇÐÀû ¾Ð·Â°ú À̿ʹ ¹Ý´ë¹æÇâÀ¸·Î ÀÛ¿ëÇÏ´Â Ç÷Àå ´Ü¹é¿¡ ÀÇÇÑ »ïÅõ¾Ð¿¡ ÀÇÇØ¼­ À¯ÁöµÇ°í ÀÖ´Ù.
  • vascular permeability factor
    Ç÷°ü Åõ°ú ÀÎÀÚ
  • vascular phenomena
    Ç÷°ü Çö»ó
  • vascular plexus
    Ç÷°üÃÑ
  • vascular pole
    Ç÷°ü ±Ø
  • vascular reaction
    Ç÷°ü ¹ÝÀÀ
  • vascular resection
    Ç÷°ü ÀýÁ¦
  • vascular ring
    Ç÷°ü·û
    ½Äµµ¿Í ±â°üÀ» À±»óÀ¸·Î µÑ·¯½Î°í, ÇùÂø Áõ»óÀ» ³ªÅ¸³½´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
immunologic and biological factors A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity.
(12 Dec 1998)
immunologic factors Biologically active substances whose activities affect or play a role in the functioning of the immune system.
(12 Dec 1998)
initiation factors The set of catalytic proteins required, in addition to mRNA and ribosomes, for protein synthesis to begin. In bacteria three distinct proteins have been identified: if 1 (8 kD), IF 2 (75 kD) and IF 3 (30 kD). at least 6-8 proteins have been identified in eukaryotes. IFs 1 and 2 enhance the binding of initiator tRNA to the initiation complex.
(18 Nov 1997)
ischemia-modifying factors Various factors that play a role in determining the extent of necrosis with cerebral stroke; these include blood viscosity and osmolality, the blood pressure, and the anatomy of the neck and intracranial arteries.
(05 Mar 2000)
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
thyroid carcinoma risk factors <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma
(12 Dec 1998)
time factors Elements of limited time intervals, contributing to particular results or situations.
(12 Dec 1998)
transcription factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
(12 Dec 1998)
transcription factors, tfii The so-called general transcription factors that bind to RNA polymerase II and that are required to initiate transcription. They include tfiia, tfiib, tfiid, tfiie, tfiif, tfiih, tfii-I, and tfiij. In vivo they apparently bind in an ordered multi-step process and/or may form a large preinitiation complex called RNA polymerase II holoenzyme.
(12 Dec 1998)
transcription factors, tfiii Factors that bind to RNA polymerase III and aid in transcription. They include the assembly factors tfiiia and tfiiic and the initiation factor tfiiib. All combine to form a preinitiation complex at the promotor that directs the binding of RNA polymerase III.
(12 Dec 1998)
epidemiologic factors Events, characteristics, or other definable entities that have the potential to bring about a change in a health condition or other defined outcome.
(12 Dec 1998)
essential food factors Those substances required in the diet: certain amino acids and unsaturated fatty acids, vitamins, essential minerals, etc.
(05 Mar 2000)
Factors I XII <haematology> Blood clotting factors, especially from humans. These factors form a cascade in which the activation of the first factor leads to enzymic attack on the next factor and so on, finally resulting in blood clotting.
(18 Nov 1997)
uncoupling factors Substances such as dinitrophenol that allow oxidation in mitochondria to proceed without the usual concomitant phosphorylation to produce ATP; these poisons thus "uncouple" oxidation and phosphorylation.
Synonym: uncoupling factors.
(05 Mar 2000)
lactose factors Plasmids which determine the ability of a bacterium to ferment lactose.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á